Liaoning Chengda Biotechnology Co Ltd
SSE:688739

Watchlist Manager
Liaoning Chengda Biotechnology Co Ltd Logo
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Watchlist
Price: 26.71 CNY -4.02% Market Closed
Market Cap: 4.9B CNY
Have any thoughts about
Liaoning Chengda Biotechnology Co Ltd?
Write Note

Liaoning Chengda Biotechnology Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Liaoning Chengda Biotechnology Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Cost of Revenue
-ÂĄ342.6m
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-ÂĄ2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-ÂĄ992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cost of Revenue
-ÂĄ5B
CAGR 3-Years
-54%
CAGR 5-Years
-46%
CAGR 10-Years
-33%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-ÂĄ35.1B
CAGR 3-Years
-49%
CAGR 5-Years
-51%
CAGR 10-Years
-62%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-ÂĄ140.8m
CAGR 3-Years
-36%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Liaoning Chengda Biotechnology Co Ltd
Glance View

Market Cap
4.9B CNY
Industry
Biotechnology

Liaoning Chengda Biotechnology Co., Ltd. is engaged in the research, development, manufacture and sale of vaccines. The company is headquartered in Shenyang, Liaoning and currently employs 1,663 full-time employees. The company went IPO on 2021-10-28. The firm's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The firm's products include two brands: Chengda Suda and Chengda Libao.

Intrinsic Value
34.95 CNY
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Liaoning Chengda Biotechnology Co Ltd's Cost of Revenue?
Cost of Revenue
-342.6m CNY

Based on the financial report for Dec 31, 2023, Liaoning Chengda Biotechnology Co Ltd's Cost of Revenue amounts to -342.6m CNY.

What is Liaoning Chengda Biotechnology Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-10%

Over the last year, the Cost of Revenue growth was -41%. The average annual Cost of Revenue growth rates for Liaoning Chengda Biotechnology Co Ltd have been -7% over the past three years , -10% over the past five years .

Back to Top